3 Healthcare Stocks With Revenue Growth Up To 34%

When a critical PHP security flaw forces governments and companies worldwide to take sites offline, attention turns to services that are essential no matter what happens online. Healthcare fits that bill. People still need treatment, diagnostics and medicines in every cycle. That reliability is one reason financially robust healthcare businesses can appeal to long term investors. This article highlights three financially solid healthcare stocks from our curated screener that may merit a closer look.

The three stocks that follow are only a small sample, and the full screen surfaced 36 more healthcare businesses with equally compelling stories that are not covered here. To identify your own highest conviction ideas across providers, biotech, pharma and healthcare tech, analyze the full Best Healthcare Stocks screener.

Eton Pharmaceuticals (ETON)

Overview: Eton Pharmaceuticals is a US rare-disease specialist that markets approved treatments and develops new therapies for highly targeted patient groups.

Operations: Eton generates about $106 million by developing and commercializing prescription drug products in the United States, reflecting a focused rare-disease portfolio.

Market Cap: $1.43b

Eton Pharmaceuticals slots into the Best Healthcare Stocks screener as a focused rare-disease drug developer whose approved products already serve patients with highly specific conditions.

"Strategic expansion and commercialization of ultra-rare and orphan drugs, including new product launches (Khindivi, ET-600), potential label expansions, and pipeline development, positions Eton to benefit from regulatory incentives and premium pricing, supporting both top-line revenue growth and improved gross margins."

What happens to Eton Pharmaceuticals’ valuation story if a single assumption about future rare-disease pricing power or reimbursement pressure breaks?

If that single pressure point matters to you, read the full narrative for Eton Pharmaceuticals to see how Eton Pharmaceuticals’ rare-disease focus could still accelerate the broader equity story.

GeneDx Holdings (WGS)

Overview: GeneDx Holdings provides genetic testing and AI-supported genomic analysis, helping doctors diagnose pediatric and rare diseases using whole exome and whole genome sequencing.

Operations: GeneDx generates about $454 million in sales, primarily from United States customers, with $423 million linked to Segment Adjustment and $31 million from Fabric Genomics and Legacy Sema4.

Market Cap: $2.05b

GeneDx Holdings matters for this Best Healthcare Stocks screener because its genetic reports sit directly in the care pathway for complex pediatric and rare disease cases, turning raw genomic data into decisions that doctors and families rely on.

"Rapid long-term reimbursement gains from Medicaid and commercial payers are unlikely to be sustainable as government cost-containment efforts intensify in response to rising healthcare spending, increasing the risk that reimbursement rates for advanced diagnostics will decline and directly pressure GeneDx's future revenue growth and gross margins."

For long term investors, a single unresolved question around future payer behavior could be the swing factor that reshapes GeneDx Holdings’ earnings power.

That single swing factor is exactly why reading the full narrative for GeneDx Holdings can help you see whether reimbursement risk is masking a stronger GeneDx Holdings trajectory.

Axogen (AXGN)

Overview: Axogen develops and supplies peripheral nerve repair implants and related services that help surgeons restore function after nerve injuries.

Operations: Axogen generates about $251 million almost entirely from peripheral nerve repair products and related services in the United States.

Market Cap: $2.12b

Axogen matters for this Best Healthcare Stocks screen because its peripheral nerve repair products give surgeons a practical toolkit for complex reconstructive procedures where reliable outcomes really influence long term hospital adoption and patient demand.

"Upcoming FDA Biologics License Application (BLA) approval for Avance Nerve Graft in September 2025 is expected to secure 12 years of market exclusivity and establish Avance as the only biologic with this indication, which should drive pricing power, limit biosimilar competition, and boost both gross margin and long-term earnings visibility."

What happens to Axogen’s margin story if there is a quiet shift in how payers or hospitals value premium nerve repair that changes the pricing equation?

If that pricing shift is what you are weighing, read the full narrative for Axogen to see how Axogen’s nerve repair story could still be accelerating quietly.

Still Seeking Fresh Investing Alternatives

Momentum can shift fast, and the next breakout ideas often fly under the radar for now. Scan fresh opportunities before the crowd catches up and act now.

• Spot cash generative companies before momentum traders notice by scanning a curated list of solid balance sheet and fundamentals (25 results) that rewards patience and disciplined risk control.
• Target fast-moving opportunities in future technology by reviewing the curated 55 AI infrastructure stocks before sentiment swings and ideal entry ranges start dropping out of reach.
• Hunt for under-the-radar potential in automation by checking a hand-picked set of 93 robotics and automation stocks while valuations still look grounded and expectations remain contained.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com